The Senate approved a handful of amendments by unanimous consent on Wednesday (see below), and will hold about a dozen votes before coming to the final bill. The legislation, S. 3187, is generally non-controversial, and would reauthorize and extend a user-fee program that drug and medical device industry groups support as a way of speeding up the FDA approval process.
As part of a deal announced Wednesday, Republicans won the right to have a vote on their alternative plan, which would terminate a preventive health fund created in 2010.
But approval of both the GOP alternative and the Democratic bill will need 60 votes to pass. Because each party seems to genuinely hate the other's bill, the votes might well be a setup for partisan finger-pointing once both fail, which will at least give the parties something to talk about over the long Memorial Day weekend.
The Senate should also approve a 60-day extension of the National Flood Insurance Program at some point today. Senate Majority Leader Harry ReidHarry ReidThe DC bubble is strangling the DNC Dems want Sessions to recuse himself from Trump-Russia probe Ryan says Trump, GOP 'in complete sync' on ObamaCare MORE (D-Nev.) said Wednesday that he would agree to tackle a longer-term reform bill once the Senate returns from its Memorial Day week off.
Also up today, a likely vote on a bill to extend the National Flood Insurance Program (NFIP) for 60 days, also part of Wednesday's announcement.
In a unanimous-consent vote Wednesday, the Senate approved H.R. 4097, the John F. Kennedy Center Reauthorization Act, and the following six amendments to the FDA bill, from:
• Sen. Ben CardinBen CardinSenate confirms first nominees of Trump era Dem senators to Trump pick: Probe if adviser violated Russia sanctions Live coverage: Senators grill Trump's Treasury pick MORE (D-Md.), to ensure that adequate information is disseminated to healthcare providers and payers about the potential benefits and risks of medical products on all patient populations, particularly underrepresented sub-populations, including racial subgroups;
• Cardin, to require the commissioner of Food and Drugs to report to Congress on issues with respect to small businesses;
• Sen. Chuck GrassleyChuck GrassleyGOP senator: Trump budget chief could face confirmation 'problems' Jeff Sessions will protect life Justice, FBI to be investigated over Clinton probes MORE (R-Iowa), to provide employee protections for the Commissioned Corps of the Public Health Service Act;
• Grassley, to provide deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act;
• Sen. Joe ManchinJoe ManchinOvernight Cybersecurity: Dems split on Manning decision | Assange looking to make deal What we learned from Rick Perry's confirmation hearing Manning commutation sparks Democratic criticism MORE (D-W.Va.), to reclassify the pain reliever hydrocodone under the Controlled Substances Act; and
• Sen. Jack ReedJack ReedSenate seeks deal on Trump nominees Senate seeks deal on Trump nominees Senate panel easily approves waiver for Mattis MORE (D-R.I.), to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.